Compare Stocks: MESO, ALKS, IMVT, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$43.39 -7.1%	$48.98	$26.99 ▼ $55.67	$7.28B	0.31	1.34 million shs	6.94 million shs
IMVT Immunovant	$36.95 -1.9%	$40.16	$14.58 ▼ $45.42	$7.63B	0.81	1.12 million shs	2.94 million shs
MESO Mesoblast	$15.13 +1.7%	$16.18	$13.05 ▼ $21.50	$1.97B	2.12	182,560 shs	214,720 shs
RYTM Rhythm Pharmaceuticals	$97.71 -1.3%	$107.24	$74.50 ▼ $122.20	$6.70B	1.97	496,097 shs	1.12 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-5.61%	-9.64%	-3.56%	+55.69%
IMVT Immunovant	0.00%	-1.10%	-16.69%	+4.56%	+144.54%
MESO Mesoblast	0.00%	-2.26%	-13.20%	+5.29%	+0.40%
RYTM Rhythm Pharmaceuticals	0.00%	-6.69%	-10.29%	+0.95%	+1.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$43.39 -7.1%	$48.98	$26.99 ▼ $55.67	$7.28B	0.31	1.34 million shs	6.94 million shs
IMVT Immunovant	$36.95 -1.9%	$40.16	$14.58 ▼ $45.42	$7.63B	0.81	1.12 million shs	2.94 million shs
MESO Mesoblast	$15.13 +1.7%	$16.18	$13.05 ▼ $21.50	$1.97B	2.12	182,560 shs	214,720 shs
RYTM Rhythm Pharmaceuticals	$97.71 -1.3%	$107.24	$74.50 ▼ $122.20	$6.70B	1.97	496,097 shs	1.12 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-5.61%	-9.64%	-3.56%	+55.69%
IMVT Immunovant	0.00%	-1.10%	-16.69%	+4.56%	+144.54%
MESO Mesoblast	0.00%	-2.26%	-13.20%	+5.29%	+0.40%
RYTM Rhythm Pharmaceuticals	0.00%	-6.69%	-10.29%	+0.95%	+1.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.78	Moderate Buy	$54.56	25.75% Upside
IMVT Immunovant	2.55	Moderate Buy	$44.00	19.08% Upside
MESO Mesoblast	2.00	Hold	$39.00	157.77% Upside
RYTM Rhythm Pharmaceuticals	2.76	Moderate Buy	$140.67	43.96% Upside

Current Analyst Ratings Breakdown

Latest MESO, ALKS, IMVT, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	RYTM Rhythm Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/16/2026	ALKS Alkermes	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/14/2026	RYTM Rhythm Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$133.00
8/28/2026	RYTM Rhythm Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
8/27/2026	MESO Mesoblast	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$35.00 ➝ $39.00
8/25/2026	IMVT Immunovant	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/7/2026	ALKS Alkermes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$145.00 ➝ $146.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$154.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/5/2026	RYTM Rhythm Pharmaceuticals	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$160.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.48B	4.93	$1.67 per share	25.92	$11.02 per share	3.94
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
MESO Mesoblast	$120.25M	16.34	N/A	N/A	$4.38 per share	3.45
RYTM Rhythm Pharmaceuticals	$189.76M	35.29	N/A	N/A	$2.08 per share	46.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	114.19	180.79	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
MESO Mesoblast	-$57.50M	-$0.28	N/A	42.03	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)

Latest MESO, ALKS, IMVT, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
7/31/2026	Q4 2026	MESO Mesoblast	N/A	-$0.0660	N/A	-$0.0660	N/A	$34.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
IMVT Immunovant	N/A	7.27	7.27
MESO Mesoblast	0.19	2.43	2.09
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
IMVT Immunovant	47.08%
MESO Mesoblast	1.43%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
IMVT Immunovant	1.90%
MESO Mesoblast	18.80%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
MESO Mesoblast	108	129.88 million	105.46 million	Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable

MESO, ALKS, IMVT, and RYTM Headlines

Recent News About These Companies

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated at Wolfe Research

September 19 at 1:54 AM | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated by Analysts at Wolfe Research

September 17 at 9:05 AM | marketbeat.com

RBC Capital Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

September 17 at 8:51 AM | theglobeandmail.com

J.P. Morgan Remains a Buy on Rhythm Pharmaceuticals (RYTM)

September 17 at 8:51 AM | theglobeandmail.com

Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform

September 17 at 8:51 AM | marketscreener.comM

Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Down 5.3% After Insider Selling

September 17 at 1:20 AM | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated at Leerink Partners

September 16, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling

September 15, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO David Meeker Sells 50,000 Shares

September 15, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells $5,133,500.00 in Stock

September 15, 2026 | insidertrades.com

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells 50,000 Shares of Stock

September 14, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Analysts at Leerink Partners

September 14, 2026 | marketbeat.com

California State Teachers Retirement System Lowers Stake in Rhythm Pharmaceuticals, Inc. $RYTM

September 14, 2026 | marketbeat.com

Head-To-Head Survey: Generate Biomedicines (NASDAQ:GENB) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM)

September 12, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals Presents New Data on Setmelanotide Therapy and Phase 3 Analyses At European Society for Paediatric Endocrinology Meeting

September 11, 2026 | marketscreener.comM

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

September 10, 2026 | globenewswire.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Brokerages

September 10, 2026 | americanbankingnews.com

Squarepoint Ops LLC Buys 159,953 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

September 9, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 5, 2026 | marketbeat.com

43,908 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Acquired by Legal & General Group Plc

September 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MESO, ALKS, IMVT, and RYTM Company Descriptions

Alkermes NASDAQ:ALKS

$43.39 -3.32 (-7.11%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$43.34 -0.05 (-0.11%)

As of 09/18/2026 07:30 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Immunovant NASDAQ:IMVT

$36.95 -0.70 (-1.86%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$36.95 0.00 (0.00%)

As of 09/18/2026 07:41 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Mesoblast NASDAQ:MESO

$15.13 +0.26 (+1.75%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$15.12 -0.01 (-0.07%)

As of 09/18/2026 07:44 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Rhythm Pharmaceuticals NASDAQ:RYTM

$97.71 -1.31 (-1.32%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$97.74 +0.03 (+0.03%)

As of 09/18/2026 07:30 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MESO, ALKS, IMVT, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MESO, ALKS, IMVT, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MESO, ALKS, IMVT, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MESO, ALKS, IMVT, and RYTM Company Descriptions

Alkermes NASDAQ:ALKS

Immunovant NASDAQ:IMVT

Mesoblast NASDAQ:MESO

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MESO, ALKS, IMVT, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MESO, ALKS, IMVT, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MESO, ALKS, IMVT, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MESO, ALKS, IMVT, and RYTM Company Descriptions

Alkermes NASDAQ:ALKS

Immunovant NASDAQ:IMVT

Mesoblast NASDAQ:MESO

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools